PP
MRNA icon

PDT Partners’s Moderna MRNA Stock Holding History

PDT Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,378
Closed -$1.03M – 672
2025
Q2 		$1.03M Sell
37,378
-181,617
-83% -$4.78M 0.06% 416
2025
Q1 		$6.21M Buy
218,995
+212,250
+3,147% +$7.53M 0.44% 36
2024
Q4 		$280K Sell
6,745
-14,555
-68% -$696K 0.02% 595
2024
Q3 		$1.42M Sell
21,300
-18,390
-46% -$1.69M 0.13% 293
2024
Q2 		$4.71M Buy
39,690
+3,989
+11% +$505K 0.45% 36
2024
Q1 		$3.8M Sell
35,701
-1,499
-4% -$151K 0.36% 70
2023
Q4 		$3.7M Buy
37,200
+25,490
+218% +$2.14M 0.41% 51
2023
Q3 		$1.21M Buy
+11,710
New +$1.31M 0.15% 233
2021
Q4 		– Sell
-1,910
Closed -$735K – 962
2021
Q3 		$735K Buy
+1,910
New +$704K 0.05% 402
2020
Q3 		– Sell
-12,263
Closed -$787K – 804
2020
Q2 		$787K Sell
12,263
-19,573
-61% -$1.07M 0.05% 320
2020
Q1 		$953K Sell
31,836
-7,541
-19% -$173K 0.08% 233
2019
Q4 		$770K Buy
+39,377
New +$699K 0.05% 328

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PDT Partners's MRNA Position: Q3 2025 in Review

PDT Partners sold out of Moderna (MRNA) in Q3 2025, closing a stake of 37,378 shares — an estimated $1.03M sold.

PDT Partners first reported a position in MRNA in Q4 2019 and held it in 12 quarters. The position peaked at $6.21M in Q1 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • PDT Partners reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 37,378 Moderna shares in Q3 2025, an estimated $1.03M.
  • PDT Partners first reported a position in Moderna in Q4 2019 and held it in 12 quarters.
  • PDT Partners's Moderna position peaked at $6.21M in Q1 2025.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.